Sign In
Buy CYCC
$6.37
+0 (+0%)
At Close: Dec 10, 2025
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call Transcript
10:40pm, Thursday, 25'th Feb 2021
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
07:46am, Monday, 11'th Jan 2021
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Inve
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
07:00am, Wednesday, 30'th Dec 2020
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript
09:08pm, Wednesday, 11'th Nov 2020
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals to Release Third Quarter Financial Results
09:29am, Thursday, 05'th Nov 2020
BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative med
A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib A patient with MCL1 amplified endometrial cancer achieved par
Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results
08:05pm, Wednesday, 12'th Aug 2020
\- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -BERKELEY HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "
Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results
11:00am, Wednesday, 05'th Aug 2020
BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
03:46pm, Tuesday, 28'th Jul 2020
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock Passes Above 200 Day Moving Average of $2.43
01:56am, Tuesday, 14'th Jul 2020
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.43 and traded
Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer
11:00am, Monday, 13'th Jul 2020
\-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1,.
VITRAC Therapeutics Initiated Global Clinical Development of VIC-1911, licensed from Taiho Pharmaceutical
12:00am, Monday, 29'th Jun 2020
VITRAC Therapeutics, LLC (VITRAC) initiated the global clinical development of VIC-1911, an oncology candidate formally known as TAS-119, which was li
CDK Global Inc (NASDAQ:CDK) Shares Bought by Nuveen Asset Management LLC
06:54am, Wednesday, 17'th Jun 2020
Nuveen Asset Management LLC grew its stake in shares of CDK Global Inc (NASDAQ:CDK) by 26.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange
CDK Global Inc (NASDAQ:CDK) Shares Sold by Alliancebernstein L.P.
08:20am, Monday, 15'th Jun 2020
Alliancebernstein L.P. cut its position in shares of CDK Global Inc (NASDAQ:CDK) by 0.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor
CDK Global Inc (NASDAQ:CDK) Shares Acquired by Pictet Asset Management Ltd.
07:16am, Sunday, 14'th Jun 2020
Pictet Asset Management Ltd. lifted its holdings in shares of CDK Global Inc (NASDAQ:CDK) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exc
